Evidence map›Paper›PMID 35218083›Full record

ArticleJournal of clinical laboratory analysis2022

Validation of the hepatocellular carcinoma early detection screening algorithm Doylestown and aMAP in a cohort of Chinese with cirrhosis.

Yunsong Qian, Linhong Li, Li Ma, Rengbin Ji, Sheng Ying, Juhong Zhou, Liyun Fu, Gang Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Hepatocellular Carcinoma: The Search for an Optimal Screening Test.Middle East journal of digestive diseases · 2025
    Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yunsong QianDepartment of Infection and Hepatology, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, China.ORCID https://orcid.org/0000-0002-2026-3508
Linhong LiResearch and Development Division, Oriomics Biotech, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0002-1732-3020
Li MaDepartment of Infection and Hepatology, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, China.ORCID https://orcid.org/0000-0003-4732-7310
Rengbin JiDepartment of Infection and Hepatology, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, China.ORCID https://orcid.org/0000-0002-4632-0689
Sheng YingDepartment of Infection and Hepatology, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, China.ORCID https://orcid.org/0000-0002-0791-0491
Juhong ZhouResearch and Development Division, Oriomics Biotech, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0001-8323-7051
Liyun FuDepartment of Infection and Hepatology, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, China.ORCID https://orcid.org/0000-0001-7025-5162
Gang YangDepartment of Infection and Hepatology, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, China.ORCID https://orcid.org/0000-0001-6524-9710
Ningbo No. 2 Hospital · CNHangzhou DAC Biotech (China) · CN

Funding

Applied Research Projects on Nonprofit Technology of Zhejiang Province LGF19H160012Key Laboratory of Diagnosis and Treatment of Digestive System tumors of Zhejiang Province 2019E10020Major national science and technology projects 2018ZX10301202-006-003Natural Science Foundation of Ningbo 202003N4020Natural Science Foundation of Zhejiang Province LQ19H160007Ningbo Clinical Research Center for Digestive System tumors 2019A21003Ningbo HwaMei Key Research Fund 2019HMZD13Ningbo HwaMei Key Research Fund 2019HMZD19Ningbo HwaMei Key Research Fund 2020HMZD10
6 · The paper itself

Abstract

backgroundPrevious studies have developed some blood-based biomarker algorithms such as the Doylestown algorithm and aMAP score to improve the detection of Hepatocellular carcinoma (HCC). However, no one has studied the application of the Doylestown algorithm in the Chinese. Meanwhile, which of these two screening models is more suitable for people with liver cirrhosis remains to be investigated.

methodsIn this study, HCC surveillance was performed by radiographic imaging and testing for tumor markers every 6 months from August 21, 2018, to January 12, 2021. We conducted a retrospective study of 742 liver cirrhosis patients, and among them, 20 developed HCC during follow-up. Samples from these patients at three follow-up time points were tested to evaluate alpha-fetoprotein (AFP), the Doylestown algorithm, and aMAP score.

resultsOverall, 521 liver cirrhosis patients underwent semiannual longitudinal follow-up three times. Five patients were diagnosed with HCC within 0-6 months of the third follow-up. We found that for these liver cirrhosis patients, the Doylestown algorithm had the highest accuracy for HCC detection, with areas under the receiver operating characteristic curve (AUCs) of 0.763, 0.801, and 0.867 for follow-ups 1-3, respectively. Compared with AFP at 20 ng/ml, the Doylestown algorithm increased biomarker performance by 7.4%, 21%, and 13% for follow-ups 1-3, respectively.

conclusionsOur findings show that the Doylestown algorithm performance appeared to be optimal for HCC early screening in the Chinese cirrhotic population when compared with the aMAP score and AFP at 20 ng/ml.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAlgorithmsalpha-FetoproteinsBiomarkers, TumorChinaHumansLiver CirrhosisRetrospective StudiesSensitivity and Specificityalpha-FetoproteinsBiomarkers, Tumoralpha-fetoproteinaMAP scoreDoylestown algorithmearly screeninghepatocellular carcinoma

Identifiers

PMID35218083
PMCPMC8993634
OpenAlexW4214569767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.